Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

a cutting-edge cancer treatment that targets specific cancer cells. This is just one example of the company’s diverse and promising pipeline. Eli Lilly and Company (NYSE:LLY) holds a strong ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

(Bloomberg) -- President Donald Trump said he plans to order a cut in US prescription drug costs to bring them in line with ... to Wegovy, Lilly said on Sunday. Eli Lilly and Company (NYSE ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Eli Lilly and Novo Nordisk dominate the ... agonist candidate in phase 2 trials at the moment. Lilly's leap closer to the finish line But Lilly is ahead of the pack and just took a leap closer ...